C0414 - IBD 101: Three-Year Follow-Up of a Primer for First-Year GI Fellows

Monday, October 24, 2022

3:00 PM – 5:00 PM ET

Location: Crown Ballroom

Presenting Author(s)

Simon Hong, MD

NYU Langone
New York, NY

Simon Hong, MD¹, Sunanda Kane, MD, MSPH², David Hudesman, MD³, David T. Rubin, MD, FACG⁴, Lisa Malter, MD⁵
¹NYU Langone, New York, NY; ²Mayo Clinic, Rochester, MN; ³NYU Langone Health, New York, NY; ⁴University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL; ⁵NYU/Bellevue, New York, NY

Introduction: The care of inflammatory bowel disease (IBD) has become increasingly complex and specialized. IBD education of gastroenterology (GI) trainees needs improvement and standardization. IBD 101, an annual course designed to introduce first-year GI fellows to various clinical topics in the management of IBD, was held on September 14, 2019. In this inaugural program, a select group of fellows (N=55 from 32 different programs) participated in a one-day course involving small group didactic sessions and Group Observed Structured Clinical Examinations (OSCEs) led by expert faculty members in seven clinical topics.

Methods: To assess the long-term impact of IBD 101, email surveys were administered in May 2022 (the graduating year of the inaugural IBD 101 cohort) to all third-year GI fellows from participating programs, inclusive of both attendees and non-attendees. The primary outcome was comfort level discussing the 7 topics addressed at IBD 101, graded using a Likert scale (1= “strongly disagree” to ”4= “strongly agree”). Information regarding each fellow’s exposure to IBD education was collected.

Results: Thirty-six fellows completed surveys, of whom 21 (58%) were IBD 101 attendees and 15 (42%) were non-attendees. Overall, attendees reported equivalent or higher levels of comfort in each of the 7 topics than did non-attendees (Figure 1). In particular, a higher proportion of attendees strongly agreed with comfort in discussing pregnancy and IBD (43% vs. 13%; P=0.04) and loss of response to biologics (62% vs. 27%; P=0.13) than non-attendees. When assessing overall confidence, 76% of attendees reported comfort in all 7 categories, compared with 53% of non-attendees (P=0.15). Attending IBD 101 was associated with overall confidence (OR 5.21 [95% CI 0.91-29.9]; P=0.06) even after adjusting for presence of an IBD specialist at a fellow’s home institution, number of IBD patients seen per month (≤5 vs. >5) and rotating through an IBD-only clinic or inpatient service (Table 1).

Discussion: IBD 101, a primer for first-year GI trainees, was associated with increased comfort in the management of IBD, with more pronounced impact on challenging topics. IBD 101 is a valuable learning opportunity for first-year GI fellows with a durable benefit independent of individual access to IBD education, and we plan continued development, expansion and assessment of this program in collaboration with the ACG to further enhance the IBD education of the pipeline of GI trainees.

Figure: IBD 101 Attendee vs. Non-Attendee Comfort Level in Addressing Various IBD Topics

	Odds Ratio [95% CI]
IBD 101 attendee	5.21 [0.91-29.9]
No. of IBD patients seen per month ( >5)	4.48 [0.80-25.2]
IBD specialist at home institution	8.30 [0.47-145.4]
Rotation in IBD-only clinic or inpatient service	2.92 [0.43-19.7)

Table: Multivariable Analysis of Factors Associated with Global Confidence in IBD 101 Topics

Disclosures:

Simon Hong indicated no relevant financial relationships.

Sunanda Kane: Boehringer Ingelheim – Consultant. Bristol Myers Squibb – Consultant, Grant/Research Support. InveniAI – Consultant. Janssen – Consultant. Kinetix Health – Consultant. Pfizer – Consultant. PredicaMed – Advisory Committee/Board Member. Seres Therapeutics – Consultant. Spherix – Consultant. Takeda – Consultant. United Healthcare – Consultant. UpToDate – Editor.

David Hudesman: Abbvie – Consultant. Bristol Myers Squibb – Consultant. Janssen – Consultant, Grant/Research Support. Pfizer – Consultant, Grant/Research Support. Takeda – Consultant.

David Rubin: AbbVie – Consultant. Alimentiv Inc. – Consultant. AltruBio – Consultant. Arena Pharmaceuticals – Consultant. Aslan Pharmaceuticals – Consultant. Athos Therapeutics – Consultant. Bellatrix Pharmaceuticals – Consultant. Boehringer Ingelheim, Ltd. – Consultant. Bristol Myers Squibb – Consultant. Celgene Corp/Syneos – Consultant. ClostraBio – Consultant. Connect BioPharma – Consultant. EcoR1 – Consultant. Genentech/Roche – Consultant. Gilead Sciences – Consultant. Ironwood Pharmaceuticals – Consultant. Iterative Scopes – Consultant. Janssen – Consultant. Kaleido Biosciences – Consultant. Lilly, Eli & Co – Consultant. Materia Prima – Consultant. Pfizer – Consultant. Prometheus Biosciences – Consultant. Reistone Biopharma – Consultant. Seres Therapeutics, Inc – Consultant. Takeda – Consultant, Grant/Research Support. Target RWE – Consultant. Techlab – Consultant. Trellus Health – Consultant.

Lisa Malter: Abbvie – Advisory Committee/Board Member. Abbvie – Grant/Research Support. Gilead – Advisory Committee/Board Member. Janssen – Advisory Committee/Board Member. Janssen – Grant/Research Support. Merck – Advisory Committee/Board Member. Pfizer – Grant/Research Support. Takeda – Advisory Committee/Board Member. Takeda – Grant/Research Support. UCB – Grant/Research Support.

Simon Hong, MD¹, Sunanda Kane, MD, MSPH², David Hudesman, MD³, David T. Rubin, MD, FACG⁴, Lisa Malter, MD⁵. C0414 - IBD 101: Three-Year Follow-Up of a Primer for First-Year GI Fellows, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.